| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
CFO & Chief Strategy Officer
1 company
Howard Liang last filed a Form 4 in June 2021, as CFO & Chief Strategy Officer at ONC. From March 2018 to June 2021, the filings on record show 0 open-market purchases and 14 sales. Howard Liang's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Historically, Howard Liang's trades have earned a middling insider score of 59/100 across 3 rated trades. Over a 12-month horizon, all 3 of those trades were profitable, with an average 12-month return of +56.0%.
Shares as reported in the last Form 4 for each company; the most recent is from June 2021. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Jun 27, 2019 | ONC Beone Medicines Ltd. | CFO & Chief Strategy Officer | Sell | 5,876 | $9.47 | $55,652.77 | -4.6% | |
| May 21, 2019 | ONC Beone Medicines Ltd. | CFO & Chief Strategy Officer | Sale+OE | 23,200 | $130.21 | $3,020,860.40 | - | |
| May 6, 2019 | ONC Beone Medicines Ltd. | CFO & Chief Strategy Officer | Sale+OE | 1,800 | $130.01 | $234,014.04 | - | |
| Mar 19, 2018 | ONC Beone Medicines Ltd. | CFO & Chief Strategy Officer | Sale+OE | 40,000 | $160.27 | $6,410,650.94 | - |